NextCure (NXTC) Common Equity (2018 - 2026)
NextCure (NXTC) posted quarterly Common Equity of $26.7 million for Q1 2026, down 52.17% year-over-year from $55.9 million in Q1 2025, and down 23.54% quarter-over-quarter from $34.9 million in Q4 2025.
NextCure (NXTC) Common Equity (2018 - 2026) Analysis & Trends
NextCure's Common Equity history runs 9 years deep, the most recent figure standing at $26.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 52.17% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $26.7 million (down 52.17% YoY), while the FY2025 annual figure was $34.9 million, down 46.63% from the prior year.
- Common Equity for Q1 2026 stood at $26.7 million, down from $34.9 million in the prior quarter.
- The five-year high for Common Equity was $213.9 million in Q1 2022, with the low at $23.6 million in Q3 2025.
- The 5-year median for Common Equity is $99.0 million (2024), against an average of $105.4 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity dropped 23.36% in 2022, then slumped 68.72% in 2025.
- NextCure's Common Equity stood at $167.5 million in 2022, then tumbled by 31.7% to $114.4 million in 2023, then plunged by 42.78% to $65.5 million in 2024, then slumped by 46.63% to $34.9 million in 2025, then declined by 23.54% to $26.7 million in 2026.
- Business Quant data shows NXTC's Common Equity at $26.7 million in Q1 2026, $34.9 million in Q4 2025, and $23.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 12.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.15 Mn |
| Mar 31, 2026 | 26.72 Mn |
| Dec 31, 2025 | 34.94 Mn |
| Sep 30, 2025 | 23.65 Mn |
| Jun 30, 2025 | 29.65 Mn |
| Mar 31, 2025 | 55.86 Mn |
| Dec 31, 2024 | 65.47 Mn |
| Sep 30, 2024 | 75.59 Mn |
| Jun 30, 2024 | 85.44 Mn |
| Mar 31, 2024 | 99.05 Mn |
| Dec 31, 2023 | 114.42 Mn |
| Sep 30, 2023 | 126.45 Mn |
| Jun 30, 2023 | 138.43 Mn |
| Mar 31, 2023 | 154.20 Mn |
| Dec 31, 2022 | 167.53 Mn |
| Sep 30, 2022 | 181.54 Mn |
| Jun 30, 2022 | 198.20 Mn |
| Mar 31, 2022 | 213.94 Mn |
| Dec 31, 2021 | 233.39 Mn |
| Sep 30, 2021 | 248.23 Mn |